Neos Therapeutics to Present at the Wells Fargo Healthcare Conference
August 29 2018 - 7:30AM
Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully integrated
pharmaceutical company focused on developing, manufacturing and
commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery technologies, today
announced that Jerry McLaughlin, Chief Executive Officer of Neos
Therapeutics, will present a company overview at the upcoming Wells
Fargo 2018 Healthcare Conference on Wednesday, September 5, 2018 at
2:25 p.m. ET in Boston, MA.
A live webcast of the presentation will be
available on the Investor Relations page of the company’s website
at http://investors.neostx.com/. Following the presentation, a
replay of the webcast will be available on Neos’ website for 30
days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a
pharmaceutical company focused on developing, manufacturing and
commercializing products utilizing its proprietary modified-release
drug delivery technology platforms. Adzenys XR-ODT® (amphetamine)
extended-release orally disintegrating tablets (see Full
Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™
(methylphenidate) extended-release orally disintegrating tablets
(see Full Prescribing Information, including Boxed WARNING), and
Adzenys-ER™ (amphetamine) extended-release oral suspension (see
Full Prescribing Information, including Boxed WARNING), all for the
treatment of ADHD, are the first three approved products using the
Company’s extended-release technology platform. In addition,
Neos manufactures and markets its generic version of the branded
product Tussionex®1, an extended-release oral suspension of
hydrocodone and chlorpheniramine for the relief of cough and upper
respiratory symptoms of a cold (see Full Prescribing Information,
including Boxed WARNING). Additional information about Neos is
available at www.neostx.com.
1Tussionex® is a registered trademark of
the UCB Group of Companies.
Contacts:
Richard EisenstadtChief Financial OfficerNeos
Therapeutics(972) 408-1389reisenstadt@neostx.com
Sarah McCabeStern Investor Relations, Inc.(212)
362-1200sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024